ArticleHepatology communications2026
Measuring MMP-7 levels in dried blood spots appears not feasible for newborn screening of biliary atresia.
Article in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBiliary atresia (BA) is an obstructive cholangiopathy of the newborn. Early diagnosis improves outcomes, but due to rarity and nonspecific presentation, referral is often delayed. Incorporation of BA into newborn screening (NBS) using dried blood spots (DBS) is desirable. Matrix metalloproteinase 7 (MMP-7) is a highly specific and sensitive marker for BA in serum and DBS and has been proposed as an appropriate screening parameter. We aimed to evaluate MMP-7 levels in DBS from patients with BA to assess its potential for NBS. STUDY
designOriginal DBS NBS cards of infants with BA (n=49) were retrospectively obtained from screening laboratories. Additional DBS and blood samples were collected at Kasai portoenterostomy (n=5). To assess MMP-7 stability, a fresh DBS sample was stored at different intervals before freezing. Healthy newborns served as controls (n=24). MMP-7 was measured by ELISA and correlated with BA type, outcome, fibrosis score, and bilirubin levels. Diagnostic performance was assessed by ROC analysis in both the study cohort and a modeled real-world prevalence setting.
resultsPatients with BA showed significantly higher MMP-7 levels than controls (BA 22.80 ng/mL±12.28, HC 13.82 ng/mL±2.97, p<0.001). Exploratory stability assessment suggested a time-dependent decrease in MMP-7 concentrations during room temperature storage, which appeared moderate within the initial days. MMP-7 levels at birth did not correlate with clinical parameters at Kasai portoenterostomy. ROC analysis demonstrated good test performance within our study cohort; however, extrapolation to real-world prevalence yielded insufficient screening performance.
conclusionsMMP-7 is elevated in BA patients' DBS at birth, but current performance characteristics are insufficient for reliable NBS. Larger studies and multiparametric approaches may be needed to improve screening feasibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.